Dr. Marshall Nash

Neurology
2665 N Decatur Rd, Suite 540, 
Decatur, GA 
2665 N Decatur Rd, Suite 540, 
Decatur, GA 

Overview

Marshall Nash is a Neurologist in Decatur, Georgia. His top areas of expertise are Alzheimer's Disease and Dementia.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurology

Licenses

Psychiatry & Neurology in GA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

2665 N Decatur Rd, Suite 540, Decatur, GA 30033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

4 Total Publications

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: January 03, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Nancy Newman
Neurology
Expertise in
19
conditions
Dr. Nancy Newman
Neurology

Emory Medical Group LLC

1365 Clifton Rd NE # B, 
Atlanta, GA 
 (2.4 miles away)
404-778-5360
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nancy Newman is a Neurologist in Atlanta, Georgia. Dr. Newman is highly rated in 19 conditions, according to our data. Her top areas of expertise are Leber Hereditary Optic Neuropathy (LHON), Optic Nerve Atrophy, Pseudotumor Cerebri Syndrome, Increased Intracranial Pressure, and Embolectomy.

Stewart A. Factor
Expertise in
20
conditions
Dr. Stewart A. Factor
Neurology
Expertise in
20
conditions
Dr. Stewart A. Factor
Neurology

Emory Brain Health Center

12 Executive Park Drive Northeast, 
Atlanta, GA 
 (3.4 miles away)
404-778-3444
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stewart Factor is a Neurologist in Atlanta, Georgia. Dr. Factor has been practicing medicine for over 44 years is highly rated in 20 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Movement Disorders, Tardive Dyskinesia, Deep Brain Stimulation, and Thalamotomy.

Hyder A. Jinnah
Expertise in
15
conditions
Dr. Hyder A. Jinnah
Neurology
Expertise in
15
conditions
Dr. Hyder A. Jinnah
Neurology

Emory Brain Health Center

12 Executive Park Drive Northeast, 
Atlanta, GA 
 (3.4 miles away)
404-778-3444
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hyder Jinnah is a Neurologist in Atlanta, Georgia. Dr. Jinnah has been practicing medicine for over 33 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Benign Essential Blepharospasm, Drug Induced Dyskinesia, Focal Dystonia, Torticollis, and Deep Brain Stimulation.

Frequently Asked Questions about Dr. Marshall Nash

How do I make an appointment with Dr. Marshall Nash?

You can book an appointment with Dr. Marshall Nash by calling their office at 404-508-4008. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marshall Nash a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marshall Nash is classified as an Experienced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marshall Nash specialize in?

While Dr. Marshall Nash is a Neurology, they have specific expertise in Alzheimer's Disease, Dementia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Marshall Nash participate in research or clinical trials?

Yes. Dr. Marshall Nash has published 4 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Marshall Nash's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marshall Nash accept my insurance?

Dr. Marshall Nash accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-508-4008 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nash's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile